AstraZeneca says its antibody treatment for people exposed to coronavirus is not effective

The results of the treatment were ‘not statistically significant’ said the drugmaker

Related video: UK approves fourth Covid-19 vaccine, Johnson & Johnson

Leer en Español

AstraZeneca says its antibody treatment for Covid-19 does not prevent symptoms in people who have been exposed to the virus.

The drug maker announced on Tuesday its treatment, called AZD7442, reduced the risk of developing symptomatic Covid by 33 per cent, compared to the placebo, but that this was not statistically significant.

Trial participants were adults over the age of 18 with confirmed exposure to a person who had coronavirus within the past eight days.

Mene Pangalos, executive vice president of BioPharmaceuticals R&D, at the company said in a statement: “While this trial did not meet the primary endpoint against symptomatic illness, we are encouraged by the protection seen in the PCR negative participants following treatment with AZD7442.”

AZD7442 is currently being tested in several other Covid-19 prevention and treatment trials, the company said.

The full results from the trial, called Storm Chaser, will be submitted for publication in a peer-reviewed medical journal.

The company had previously agreed a deal with with the US Government to supply up to 500,000 doses of AZD7442 for $205m (£145m).

Discussions regarding next steps with the US Government are ongoing, the company confirmed.

Myron J Levin, professor of pediatrics and medicine at the University of Colorado School of Medicine, who was the principal investigator on the trial, said the drug could be effective in preventing Covid in people who have not yet been infected.

He added: “While Covid-19 vaccination efforts have been successful, there is still a significant need for prevention and treatment options for certain populations, including those unable to be vaccinated or those who may have an inadequate response to vaccination.”

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in